Bli medlem
Bli medlem

Du är här


Redsense Medical receives Notice of Allowance from U.S. Patent and Trademark Office for patent application f or the catheter sensor solution.

Redsense Medical announces today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application 16/333,571 (, "A device for monitoring hose connectors and body fluid leakage".

"This is a natural extension of our technology, which will broaden the monitoring capabilities of the Redsense Alarm and enhance patient safety even further. We are now looking forward to the patent being issued, which likely will happen in May 2021," says Patrik Byhmer, CEO of Redsense Medical AB and co-inventor of the patent together with Susanne Olausson.

The claims of the allowed patent application provides protection for a hose, or line, connector sensor and is a complement to our previous product "Venous sensor". An extending optical fiber connects the hose connector sensor to the alarm unit, which thus can monitor the assembly for fluid leakage getting trapped in the hose connector enclosure. Such connector and hose assemblies include luer locks, which are widely used in extracorporeal circuits of body fluids - for example in the connections between the blood hose and the dialysis machine and between the hose and the venous needle.

"The catheter sensor solution is already commercially available, and the claims allowed by the USPTO ensure that Redsense can continue to address the safety risks. Venous needle dislodgement is a serious issue, which we address with the venous sensor - but if the integrity of the blood circuit is compromised somewhere else, for example through the failure of a catheter luer lock, the result can be just as devastating. This hose connector sensor allows a treatment provider to quickly, reliably and firmly attach a sensor to any hose connector, while at the same time confining any leakages and even reinforcing the connector, and, if need be, to quickly remove it again without disturbance," explains Patrik Byhmer.

Redsense Medical has developed an established, proprietary technology for optical monitoring of the vascular access points in conjunction with hemodialys treatment. The Company is further building a range of optical measurement solutions for advanced wound care as an offshoot of the core technology; with optical sensors integrated in smart bandages, new possibilities open up for a more personalized and resource-efficient treatment of wounds. Redsense aims to fortify the patent portfolio around its technologies to secure a strong protection on all important regional markets.

For more information, please contact:

Patrik Byhmer, CEO Redsense Medical AB (publ)

Phone: +46 35 10 60 30

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.